Galderma will pay US$1.5 billion in cash to acquire 100% of ZO Skin Health, the physician-dispensed skin care brand founded by dermatologist Dr Zein Obagi in 2007. The transaction is expected to close in the fourth quarter of 2026 or early 2027, subject to regulatory approvals.

The price buys a business with real scale. ZO Skin Health recorded net sales of approximately $330 million in the twelve months to June 2026 and sells through a network of more than 16,500 physicians, medical spas and online accounts across more than 40 countries. Galderma will fold the brand into a dermatological skin care portfolio that already carries Cetaphil and Alastin.

Flemming Ørnskov, CEO of the Switzerland-based company, framed the deal in terms of category positioning. "This acquisition is another important step towards building the world's most innovative dermatology portfolio, strengthening our offering in an area where we already have significant capabilities," he said. "We see significant opportunities to reignite its growth through investment in innovation and commercial reach."

What does the deal change for the medical-grade skin care segment?

The acquisition sharpens Galderma's claim to what its own statement calls "the attractive growth opportunities in the fast-growing medical-grade skin care segment." ZO Skin Health sits beside Alastin in the company's dermatological skin care arm, and Galderma presented the two as complementary rather than overlapping: ZO's daily regimen-based portfolio centres on retinol- and acid-based protocols, while Alastin offers what the company describes as a "highly differentiated peptide-based regenerative pre- and post-procedure offering."

For dermatologists, plastic surgeons and aestheticians, that combination covers both daily maintenance protocols and procedure-adjacent care from a single supplier. Galderma positioned itself as "a partner of choice" for those professionals.

Dr Obagi, who signed off on the sale, endorsed the fit. "Galderma is an organisation I have long admired for its complete dedication to dermatology and its partnership with health care professionals around the world," he said. "ZO Skin Health has been my life's work, and I could not be prouder to see it join a company that shares our commitment to science and the providers who trust us every day."

How will Galderma fund and structure the transaction?

The structure is straightforward. Key terms:

• All-cash transaction, subject to customary adjustments
• Funding through existing cash reserves plus bank financing
• Lazard acts as Lead Financial Advisor; JP Morgan as Financial Advisor; Ropes & Gray LLP as Legal Advisor

Galderma plans to increase commercial investment during the first year of ownership, which it says will "strengthen the foundation for renewed growth beginning in the second year following closing." The deal is expected to be slightly dilutive to the group's core EBITDA margin in 2027, returning to a margin broadly comparable with the group average from 2028 onwards.

What should formulators and buyers watch next?

The timeline gives the industry its next markers. Regulatory approvals will determine whether closing lands in late 2026 or slips into early 2027, and the first-year commercial investment phase will test Galderma's promise to reignite growth in a brand that has delivered nearly two decades of clinically backed professional skin care. The 2028 margin guidance offers the first hard measure of whether the $1.5 billion outlay has paid off.